Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
Current Oncology (Toronto, Ont.)
|
August 10, 2012
Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience
X Zhu, N Bouganim, L Vandermeer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2012
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib
G Dranitsaris, M D Vincent, J Yu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2009
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C Simmons, N Miller, W Geddie, et al.
Current Oncology (Toronto, Ont.)
|
August 11, 2010
Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey
S Saibil, B Fitzgerald, O C Freedman, et al.
Pharmacoeconomics
|
November 10, 2001
A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy
G Dranitsaris, P Leung, R Ciotti, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Abraxane Versus Taxol For Patients with Advanced Breast Cancer: A Prospective Time and Motion Analysis from a Chinese Health Care Perspective
G Dranitsaris, B Yu, L Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2017
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G Dranitsaris, A Molassiotis, M Clemons, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 30, 2019
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
P Ryan, A McBride, D Ray, et al.
Current Oncology (Toronto, Ont.)
|
January 10, 2013
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting
N Bouganim, G Dranitsaris, S Hopkins, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 17, 2012
Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
C E Simmons, I Kuchuk, O C Freedman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
Current Oncology (Toronto, Ont.)
|
August 10, 2012
Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience
X Zhu, N Bouganim, L Vandermeer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2012
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib
G Dranitsaris, M D Vincent, J Yu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2009
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C Simmons, N Miller, W Geddie, et al.
Current Oncology (Toronto, Ont.)
|
August 11, 2010
Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey
S Saibil, B Fitzgerald, O C Freedman, et al.
Pharmacoeconomics
|
November 10, 2001
A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy
G Dranitsaris, P Leung, R Ciotti, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Abraxane Versus Taxol For Patients with Advanced Breast Cancer: A Prospective Time and Motion Analysis from a Chinese Health Care Perspective
G Dranitsaris, B Yu, L Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2017
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G Dranitsaris, A Molassiotis, M Clemons, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 30, 2019
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
P Ryan, A McBride, D Ray, et al.
Current Oncology (Toronto, Ont.)
|
January 10, 2013
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting
N Bouganim, G Dranitsaris, S Hopkins, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 17, 2012
Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
C E Simmons, I Kuchuk, O C Freedman, et al.
Page
of 5